Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check their site for yourself like I have, it's free. They frequently have follow up articles after their initial report.
I agree but that's a big IF. I believe one of the asset will be sold by year's end or the JP Morgan conference. This will signifcantly change the landscape here.
Correct "can be".
You wrote:
"1. Now they are thinking about spinning out Eltoprazine or ESS as a standalone company since each has 3 indications it could target."
Nowhere does it say AMBS is thinking about spinning it out themselves which is what you stated. Merely stating the could be there own companies or subsidiary under another company.
No i won't "tell you". Figure it out like the rest of us have. It takes time and it's not for lazy people.
Based on you comment #1 there is no point in reading the rest of your post. That is not what the company said.
To this end, the Board of Directors has given management the mandate to accelerate our partnering initiatives in order to acquire the resources necessary to move the rest of the portfolio forward. Given the diversity and robustness of our rich clinical pipeline, many options exist to best execute on this directive while preserving and/or transferring value to our shareholders along the way. The Company had previously made the decision to transact on the diagnostics portfolio in order to become a pure-play therapeutics company. We will likely take this approach one step further and also seek to transact on either ESS or Eltoprazine in order to further refine the Company’s profile into a regenerative medicine company (ESS + MANF + Phenoguard) or a neurology company (Eltoprazine + MANF + Phenoguard), and achieve economic benefit from such a transaction. In looking at the pipeline, it is critical to note the late stage nature of ESS and Eltoprazine; each of these assets, individually, could provide a pipeline for a very valuable standalone public company.
I have a great idea. Why don't you pick up the phone and make a few call, it's called DD. Then you would understand why that statement was made. But of course you will sit on the message board making illogical statements....
Yes, I can do simple man. You should be careful about constantly staring in the rearview mirror...you might run into things in front of you.
Wrong again, the SHM is December 7th not tomorrow. LOL
How many times have you heard of a SHM on a Saturday...smh
Correct. And that's just the start of this moving to it true valuation.
I am aware of the past. I will focus on the future.
Sure has been big volume the past couple days, plenty of buyers at this level. Smart money
Maybe you should give another listen to the conference, i posted the link last night. GC spoke of the ongoing study of MSPrecise and readout of those result this quarter. There were a few other tidbits of information but I don't recall them at the moment.
It was never 7 million. The AS were 13,333,333 post split. The 7 million was the OS which is now 10 million.
Worth a listen if your looking for current information:
http://www.veracast.com/webcasts/bio/investorforum2015/83104172903.cfm
lol if you say so....I suppose random posters on a message board are much more reliable....smh
lol, strapped in captian! Nice little 34,718 share bid sitting there at .61
It appears someone is accumulating share yesterday and today...maybe they know something that we don't ; )
If the spin off occurs then yes AMBS would be required to give its shareholders share of the spin off company.
Update from SeeThruEquity: Maintaining their 12 month price target of $45
http://finance.yahoo.com/news/seethruequity-issues-amarantus-bioscience-holdings-140000097.html
VERT is also normal top 3 on the bid so no concern there. New MM strong on the bid today was STXG.
Of course not. It's like 90% of what is posted on this board, pure wild speculation for the fun of it. lol
There are no certainties in the market.
Looks like the family is buying this morning.
I agree it's going to $4.00.
Good point. If it does shot up to $8.00 from here it could retrace back to $4.00 before going to $12.00....
Nope I mean $4.00. Could even be higher, much higher. The possibilities are almost endless.
Don't be surprised if it goes back to $4.00 soon.
It's always darkest before the dawn. I to believe plans are in motion to get this ship back on course. Once that occurs the puzzle piece can begin to fall into place.
The company as already stated they have scaled back on programs. And a RS from 35 million or even 150 million is unlikely.
Can you point me to that SEC filing? When is soon?
And careful with the FINRA/SEC claims. One could find themselves in trouble for such talk with no proof.
When is the last time you heard of a RS with only 35 million AS? And if they do raise the AS to 150 million in December then when is the last time you have seen a RS with only 150 million AS.....
Quite a lot of garbage posted on this board that makes absolutely ZERO sense.
Already gone...no longer list on the AMBS website.
We could be looking at an Eltoprazine partnership or sale IMO. Or it could just be cost cutting measures due to the phase 2 being put on hold for 6 months.
Nice $58k bid sitting out there.
The key personnel working on Eltoprazine are no longer with the company but we continue to get news on it...could it be positioned for a sale(or already sold?)
I disagree that is has to be bad news. Eltoprazine was his baby and the phase 2 trail is on hold for 6 months as a cost savings measure. So why keep Lowe on the payroll when the company is focusing on ESS and the DX transaction.
Great post JP and I couldn't agree more!!
Typically when retail traders/investors are most scared it's a good time to buy....only time will tell.
Looking for a heavy dose of MSPrecise news in November and early December. Only 3 way for AMBS to commercialize a diagnostic test:
1. Joint Venture
2. Partnership
3. Merger/Sale with cash upfront and/or royalties
I bought some at .44
Well unfortunately for shareholders the market says the company is worth $5.89 million.
http://www.amarantus.com
Unreal, probably worth more sold off in pieces.
Paper trial issues from the past don't diminish the fact that ESS works!! Amarantus is working closely with the FDA and the DOD. It's full steam ahead for ESS, a potential life saving product.
Maybe you should write about the people that will be saved by this product instead of focusing on past paperwork issues.
Amarantus Diagnostics expected to come on strong to close out 2015.
http://www.ddn-news.com/index.php?newsarticle=9891
LymPro and MSPrecise CLIA certifications on tap. The DX strategic transaction will likely be the driver to allow Amarantus to close on the Georgetown assay option agreement.
Interesting couple months ahead....
GC just reiterated these milestones twice this month at conferences. Given past miss-steps I believe GC and team are fairly certain the milestones will be reached or they would have pushed them out to Q1 of 2016.
That could be a real game changer here and has a high probability of happening. It would explain why the company has made ESS it's primary focus.
Nice drill down sir! Interesting weeks ahead as 2015 comes to a close. Looking for the DX transaction to come to fruition.
Here is an interview with Jeff at the Aegis conference:
Thanks for the highlights on the presentation. Having had a chance to listen yet. Good news today and sounds like more on the way. The quiet period seems to be over.